CERo Therapeutics Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia

Reuters

2025/09/08

CERo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia

Cero Therapeutics Holdings Inc. has announced an update in the Phase 1 clinical trial of its drug candidate CER-1236, targeting patients with acute myeloid leukemia (AML). The company has intensified the dosing protocol for the study, administering a second dose to the second patient in the first cohort. This modification has been approved by the Institutional Review Board based on initial pharmacokinetic data indicating cell expansion. The aim is to assess the feasibility and safety of administering multiple infusions of CER-1236. The company plans to enroll a third patient in the cohort and anticipates that the protocol adjustment will yield valuable information regarding dosing, safety, and feasibility. Results from the trial have not yet been presented but are expected to provide insights as the study progresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524746-en) on September 08, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565681498"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565681498\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565681498?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565681498","market":"nz","top_or_hot":-1,"title":"CERo Therapeutics Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CERo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cero Therapeutics Holdings Inc. has announced an update in the Phase 1 clinical trial of its drug candidate CER-1236, targeting patients with acute myeloid leukemia (AML). The company has intensified the dosing protocol for the study, administering a second dose to the second patient in the first cohort. This modification has been approved by the Institutional Review Board based on initial pharmacokinetic data indicating cell expansion. The aim is to assess the feasibility and safety of administering multiple infusions of CER-1236. The company plans to enroll a third patient in the cohort and anticipates that the protocol adjustment will yield valuable information regarding dosing, safety, and feasibility. Results from the trial have not yet been presented but are expected to provide insights as the study progresses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524746-en) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CERo Therapeutics Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCERo Therapeutics Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-08 20:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CERo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cero Therapeutics Holdings Inc. has announced an update in the Phase 1 clinical trial of its drug candidate CER-1236, targeting patients with acute myeloid leukemia (AML). The company has intensified the dosing protocol for the study, administering a second dose to the second patient in the first cohort. This modification has been approved by the Institutional Review Board based on initial pharmacokinetic data indicating cell expansion. The aim is to assess the feasibility and safety of administering multiple infusions of CER-1236. The company plans to enroll a third patient in the cohort and anticipates that the protocol adjustment will yield valuable information regarding dosing, safety, and feasibility. Results from the trial have not yet been presented but are expected to provide insights as the study progresses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524746-en) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和數據","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL3DwFcx:1","article_id":"2565681498","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565681498","pubTimestamp":1757335512,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cero Therapeutics Holdings Inc. has announced an update in the Phase 1 clinical trial of its drug candidate CER-1236, targeting patients with acute myeloid leukemia . The company has intensified the dosing protocol for the study, administering a second dose to the second patient in the first cohort. This modification has been approved by the Institutional Review Board based on initial pharmacokinetic data indicating cell expansion. The aim is to assess the feasibility and safety of administering multiple infusions of CER-1236. The company plans to enroll a third patient in the cohort and anticipates that the protocol adjustment will yield valuable information regarding dosing, safety, and feasibility. Results from the trial have not yet been presented but are expected to provide insights as the study progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","CERO":"CERo Therapeutics Holdings, Inc.","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"CERo Therapeutics在CER-1236治疗急性髓系白血病的1期试验中启动剂量强化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CERO":0.9,"NDAQ":0.9},"content_text":"CERo Therapeutics Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia\n    \n\n        Cero Therapeutics Holdings Inc. has announced an update in the Phase 1 clinical trial of its drug candidate CER-1236, targeting patients with acute myeloid leukemia (AML). The company has intensified the dosing protocol for the study, administering a second dose to the second patient in the first cohort. This modification has been approved by the Institutional Review Board based on initial pharmacokinetic data indicating cell expansion. The aim is to assess the feasibility and safety of administering multiple infusions of CER-1236. The company plans to enroll a third patient in the cohort and anticipates that the protocol adjustment will yield valuable information regarding dosing, safety, and feasibility. Results from the trial have not yet been presented but are expected to provide insights as the study progresses.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524746-en) on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}